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Circadian rhythms are endogenous oscillations
of physiological and behavioral phenomena
with period length of 24 hr. A mutation in hu-
man Period 2 (hPER2), a gene crucial for reset-
ting the central clock in response to light, is
associated with familial advanced sleep phase
syndrome (FASPS), an autosomal dominant
condition with early morning awakening and
early sleep times. The FASPS hPER2 S662G
mutation resulted in PER2 being hypophos-
phorylated by casein kinase I (CKI) in vitro. We
generated transgenic mice carrying the FASPS
hPER2 S662G mutation and faithfully recapitu-
late the human phenotype. We show that phos-
phorylation at S662 leads to increased PER2
transcription and suggest that phosphorylation
at another site leads to PER2 degradation.
Altering CKId dosage modulates the S662 phe-
notype demonstrating that CKId can regulate
period through PER2 in vivo. Modeling a natu-
rally occurring human variant in mice has
yielded novel insights into PER2 regulation.
INTRODUCTION
A wealth of data from model organisms and cell-based
studies have elucidated circadian mechanisms involving
interlocked feedback loops with transcriptional and post-
translational regulations (Harms et al., 2004; Lowrey and
Takahashi, 2004; Reppert and Weaver, 2002; Young and
Kay, 2001). Circadian regulation of the clock and clock-
related genes is complex and not fully understood (Ueda
et al., 2005). Two routes have been proposed for Per2 reg-
ulation of circadian rhythms inmammals. The first involves
a negative feedback loop in which four clock genes
(Period 1 and 2 [Per1, Per2], Cryptochrome 1 and 2[Cry1, Cry2]) are activated by heteromeric complexes of
CLOCK/BMAL1 (brain-muscle-arnt-like protein 1) acting
via E-box elements in their promoter/enhancer regions.
This activation is terminated 6–8 hr later, as Per and
Cry protein complexes accumulate in the nuclei to sup-
press transcription (Hastings and Herzog, 2004). The
time to complete this transcriptional/translational feed-
back loop, and the time it takes for Per and Cry to degrade
and derepress transcription, takes approximately 24 hr.
Per2 has been shown to inhibit transcriptional activation
by CLOCK/BMAL1 in vitro (Akashi et al., 2002; Jin et al.,
1999; Kume et al., 1999). Per2 also acts as an activator
of Bmal1 transcription. This is based on in vitro Bmal1
luciferase data (Yu et al., 2002) and Per2 knockout mutant
mice, which showed lower amplitude, phase-advanced
Bmal1 expression (Shearman et al., 2000).
Circadian period length is directly connected to PER
stability in Drosophila (Edery et al., 1994). Whether this is
true for mammals has not been established. The time of
nuclear entry and length of time core clock proteins spend
in the nucleus (prior to degradation) are thought to be
critical in regulating the period of the circadian clock
(Tamanini et al., 2005). These processes are assumed to
be highly regulated, and evidence has been provided
with in vitro systems (Nawathean and Rosbash, 2004;
Yagita et al., 2002). Although it is known that Per2 phos-
phorylation plays an important role in circadian regulation,
the exact mechanism is unclear. Furthermore, themajority
of the data regarding Per2 phosphorylation comes from
in vitro and cell-culture studies (Eide et al., 2005; Lowrey
et al., 2000; Toh et al., 2001; Yagita et al., 2002).
Ultimately, translating this information to understanding
of human clock is necessary. There is no doubt that many
aspects of clock function are conserved. However, there
are dramatic differences between Drosophila and mam-
malian clocks. Even differences between mouse and
human are certain to exist: one obvious phenotypic differ-
ence is that mice are nocturnal animals, while humans are
diurnal. Probing the genetic basis of sleep in humans first
became available with the identification of a MendelianCell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc. 59
phenotype of circadian clock function (Jones et al., 1999).
Familial advanced sleep phase syndrome (FASPS) is an
autosomal dominant, highly penetrant phenotype of early
morning awakening and early sleep times. Two genes
have now been identified that result in the FASPS pheno-
type (Toh et al., 2001; Xu et al., 2005). Study of such
mutations is different from work done in forward screens
or in knocking out genes in rodents, since phenotypes
are likely more subtle (since these families have not
been selected against during evolution). Also, missense
mutations like the ones that have been identified, having
dominant effects, are likely to teach us about functional
domains of these proteins and give insights that cannot
be gleaned from knocking out genes in rodents. To under-
stand human circadian rhythm genetics and biology, it will
be most fruitful to look at naturally occurring human
mutations and couple human work with studies in cell
culture and model organisms.
RESULTS
Further Biochemical Characterization
of hPER2 S662G
The first human genetic variant demonstrated to cause
FASPS was in the human Period 2 homolog (hPER2)
(Toh et al., 2001). The serine to glycine mutation resulted
in the PER2 polypeptide being hypophosphorylated by
casein kinase I (CKI) in vitro. Similar experiments after
introducing a negatively charged residue to mimic a phos-
phoserine lead to restoration of robust phosphorylation
by CKI.
The serine at position 662 in hPER2 is the first of five
serines spaced three amino acids apart. This SxxSxxSxx
SxxS motif is highly conserved in mammalian PER pro-
teins (Toh et al., 2001). We hypothesized that phosphory-
lation of S662 could facilitate the phosphorylation of
serines at amino acid positions 665, 668, 671, and 674
by CKI, thus regulating PER2 protein stability, nuclear
translocation, or transcriptional repressor activity (Cama-
cho et al., 2001; Nawathean and Rosbash, 2004; Yama-
moto et al., 2004). To further test this idea, we carried
out in vitro phosphorylation reactions with two peptides
of the same sequence (encompassing residues 660–674
of PER2) either with or without a phosphate group cova-
lently linked to S662 (Figure 1A). In addition, we selected
another peptide from the adenomatous polyposis coli
protein (APC, residues 1386–1402, a noncircadian and
known substrate of CKI) that had a similar motif (Sxx
SxxSxxS). In vitro kinase assays showed that the PER2
peptide with a phosphate covalently linked to the first
serine is phosphorylated at other residues by CKI. The
peptide without a phosphate at S662 is not phosphory-
lated by CKI (Figure 1B). These data suggest that S662
is not phosphorylated by CKI and that a phosphate at
S662 is required for CKI to phosphorylate other residues
in the peptide. A quantitative assay showed that an
additional 4 moles of phosphate were incorporated per
mole of Pep-2P substrate and an additional 3 moles of60 Cell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc.phosphate were incorporated per mole of APC peptide
(Figure 1C). We then carried out phosphoamino acid
analysis and showed that the threonine at position 667
Figure 1. In Vitro Phosphorylation Assay of Synthetic
Peptides
(A) Phosphorylated (Pep-2P) and unphosphorylated (Pep-2U) peptides
were used as substrates for the CKI in vitro assay. Another protein
(Adenomatous polyposis coli, APC) with a similar SxxS motif was
also studied.
(B) A comparison of initial in vitro phosphorylation rates shows that
peptide with a phosphate at S662 (Pep-2P, red) incorporates addi-
tional phosphate but Pep-2U (blue) does not. Error bars represent 1
standard deviation from the mean.
(C) Stoichiometric analysis of in vitro phosphorylation of Pep-2P (red)
and APC2 (blue). The stoichiometry of phosphate incorporation is
shown for each peptide as a function of time. Error bars represent 1
standard deviation from the mean.
(D) Phosphoamino acid analysis of Pep-2P, performed in duplicate.
Both photographic (upper panel) and autoradiographic (lower panel)
records are shown. Only the phosphoamino acid standards are at
a sufficiently high concentration to be detected by ninhydrin staining
in the photographic records. When the records are aligned with the
aid of the markers at the bottom, phosphoserine is shown to be the
only labeled phosphoamino acid.
and the tyrosine at position 672 are not targets of
CKI (Figures 1A and 1D). These results support the
hypothesis that the phosphorylation of S662 plays a crit-
ical role in the regulation of PER2 by CKI via a cascade
of phosphorylations that requires a priming event at
residue 662.
Mouse Models of hPER2 S662 Mutations
We generated mice with the PER2 S662G mutation to
study its effect on circadian clock regulation in vivo. We
also generated mice having an aspartate at position 662,
as we previously showed that this reconstitutes the ability
of the PER2 protein to be phosphorylated in vitro (Toh
et al., 2001). Mice transgenic for wild-type hPER2 were
generated as a control (S662WT). In each case, a human
bacterial artificial chromosome (BAC) was used, since it
carries the cis-acting genomic regulatory elements to
faithfully recapitulate endogenous PER2 expression.
One or two copies of the transgenes are typically inserted
into the genome on a mouse background with two wild-
type endogenous genes (Figure S1). We used a human
transgene since it is highly homologous to the mouse
gene and so that we could distinguish mRNA from the
transgene versus endogenous mouse loci. Furthermore,
specific antibodies to mouse and human Per2 isoforms
are available for comparing levels of transgene-encoded
and endogenous protein.
Two knockout models of Per2 have been reported (Bae
et al., 2001; Zheng et al., 1999). In both cases, the mice
demonstrated a shorter period prior to becoming arrhyth-
mic, but there was huge variability in the number of days in
constant darkness prior to animals becoming arrhythmic
(Bae et al., 2001; Zheng et al., 1999). So that all our ex-
periments could be performed on the same genetic back-
ground, we made the Per2ldc allele congenic on a C57BL/
6J background (henceforth referred to as Per2/).
Resulting mice had a normal period and did not become
arrhythmic (data not shown). These mice were regeno-
typed to make certain that they were Per2/. This dem-
onstrates the dramatic effect of genetic background on
the circadian phenotype.
The S662G transgenic mice showed a period (t) 2 hr
shorter than wild-type, and with the S662G transgene on
a homozygous knockout background t was even shorter
(20.7 hr, Figure 2A and Table S1). Mice with the S662G
transgene all showed a robust 4 hr phase advance of
activity rhythms in LD12:12 regardless of the number
of wild-type alleles (2 versus 0) (Figure 2B). In contrast,
the mice with the S662D transgene showed a longer t
(24.3 hr) that was further lengthened on a homozygous
knockout background (24.7 hr, Figure 2A and Table S1).
Mice from multiple lines for each transgene had identical
phenotypes (data not shown). We next tested S662G
and S662G/mPer2/ mice in LD10.5:10.5 for 7 days.
These mice were able to resume the normal ‘‘on-off’’
activity patterns as observed in other control mice (Fig-
ure 2B), suggesting that early onset of activity on-off
time is due to the shortened endogenous t of S662Gmice.Thus, despite being a nocturnal animal, mice carrying
the hPER2 gene with the glycine mutation had a pheno-
type identical to that of a human FASPSwith activity onset
4–6 hr prior to lights out and activity offset before the
lights came on. Furthermore, an aspartate at position
662, mimicking a constitutively phosphorylated serine,
led to lengthening of t (Figure 2A). Changing the charge
on this single residue (glycine-uncharged, serine-partially
charged due to phosphorylation, aspartate-mimicking
a constitutively phosphorylated residue) was sufficient
to dramatically alter the circadian t from short to long.
Both the S662G and the S662D mutations are dominant
and produce a phenotype even with two wild-type
mPer2 alleles in the background.
PER2 Nuclear Abundance Correlates
with Circadian Period
Based on working models of the mammalian clock, it was
possible that S662G exerted its effect by one or more of
the following: (1) altering PER2 stability, (2) altering PER2
nuclear translocation, or (3) changing the role of PER2 in
regulating transcription. Having established the S662G
transgenic mouse as a good model for human FASPS,
we then set out to begin molecular characterization in
these and the S662D mice. To examine the level of phos-
phorylation of hPER2 protein in S662WT, S662G, and
S662D transgenic mice on null backgrounds, we prepared
liver extracts at different time points. Human PER2 was
found predominantly in the nuclear fractions (Lee et al.,
2001) (Figure 3A).Wewere not able to observe PER2 in cy-
toplasmic fractions of liver extracts (data not shown). As
expected, the S662G+; /mice showed maximal phos-
phorylation levels at CT20, whereas S662WT and
S662D+; / mice showed a mobility shift beginning at
CT12. The intensity of mobility-shifted bands observed
in S662WT is intermediate between those seen in S662G
and S662D, particularly after the CT12 time point
(Figure 3A) consistent with biochemical data showing
that phosphorylation of four other downstream residues
is modulated by the phosphorylation state of S662. The
in vivo nuclear abundance of PER2 also correlates with
the phosphorylation state of S662 (Figure 3B).
Anti-human PER2 antibody was used to immunoprecip-
itate PER2 from liver lysates. These were treated with and
without protein phosphatase 2A (PP2A) and sodium vana-
date and run on polyacrylamide gels to assess phosphor-
ylation status of PER2. A higher molecular weight PER2
band was present in samples that were either untreated
or treated with both PP2A and the phosphatase inhibitor
(Figure 3C), demonstrating that the upper band is phos-
phorylated PER2. We cultured fibroblasts from skin biop-
sies to determine whether PER2 is also less abundant in
FASPS individuals harboring the S662G mutation. Human
PER2 was present in both the nuclear and cytoplasmic
fractions at three time points in fibroblasts from control
individuals (Figure 3D), with much higher levels in the
nuclear fractions. Fibroblasts from FASPS individuals
showed lower abundance and phosphorylation of PER2Cell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc. 61
Figure 2. Circadian Phenotypes of Transgenic Mice
(A) Locomotor activity recordings of representative mice (left column). Alternating white and dark bars indicate the LD cycles during entrainment prior
to release in DD. t analysis for each activity record is shown in the right column.
(B) Activity patterns in LD12:12. Data was accumulated in 3min bins for7 days. Shadows indicate standard error of themean. S662G/mPer2/ and
S662G mice show activity phase advance of 4–6 hr relative to mPer2/ and wt. Activity onset is similar for S662D, wt, S662D/mPer2/, and
mPer2/ mice. The activity onset is at ‘‘lights out’’ for S662G and S662G/mPer2/ mice in LD10.5:10.5. (See Table S1 for population data).than fibroblasts from control individuals, consistent with
observations in transgenic mouse liver extracts.
We also examined protein abundance in cultured fibro-
blasts from transgenic mice after cells were synchronized
by serum shock (Balsalobre et al., 1998). The level of PER2
is dramatically elevated at different time points in S662D
versus S662G (Figure 3E). Cytosolic PER2 was barely
detectable in fibroblasts from both FASPS individuals
and S662G transgenic mice (Figures 3D and 3E). Nuclear
PER2 from FASPS fibroblasts and S662G mice showed
reduced phosphorylation relative to fibroblasts from
human controls and S662D mice (Figures 3D and 3E).
These data demonstrate that hPER2 is phosphorylated62 Cell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc.later and to a lower degree in S662G mice versus wild-
type or S662D.
PER2 Mutations at Position 662 Alter Transcriptional
Regulation of Its Own Message
To examine the mRNA levels of endogenous mPer2 and
the hPER2 transgene in vivo, we entrained mice of differ-
ent genotypes to 12 hr light and 12 hr dark (LD12:12) and
then released them into constant darkness (DD). mRNA
levels in liver were assessed at different time points during
the second day in DD. Both hPER2 and endogenous
mPer2 mRNA levels peaked earlier for S662G and later
for S662D when compared to wild-type (Figures 4A and
Figure 3. PER2 S662 Phosphorylation Results in Increased PER2 Protein
(A) hPER2 abundance and phosphorylation in S662G, S662WT, and S662D transgenic mouse liver extracts (nuclear fractions) at different CTs.
(B) Quantification of protein from liver extracts in (A). Error bars represent standard deviation for each time point in three independent experiments.
Differences using the t test were statistically significant (p < 0.05) for S662G versus S662D at all time points, for S662 versus S662G at all time points
except 6 hr, and for S662 versus S662D at t = 0, 20, and 24.
(C) Immunoprecipitated complexes from S662D mouse liver at CT16 were untreated, or treated with either phosphatase alone or both phosphatase
and sodium vanadate. Changes in PER2 mobility are due to changes in phosphorylation.
(D) hPER2 from human S662G and control fibroblasts show that protein is primarily in the nuclear fractions (‘‘N’’ versus cytosolic ‘‘C’’) and that levels
of hPER2 protein were lower in S662G subjects versus controls. The star represents a nonspecific band that serves as an internal loading control.
(E) Western blot analysis of cultured fibroblasts from S662G and S662D transgenic mice. Upper and lower arrows indicate low and high mobility
hPER2 protein. hPER2 protein is undetectable in cytosolic fractions (cytosolic C) of S662G transgenic mice and are much higher (C and N)
in S662D transgenic mice.
(F) Fibroblasts were cultured and serum-shocked, and MG132 was added at t = 0 and again at 4 hr. Cells were harvested at times 4 and 8 hr. The
proteasome inhibitor MG132 does not lead to an increase in S662G hPER2 protein.
(G) Lysosome inhibitors were added to cells 2 hr after serum shock and 2 hr before cells were harvested at times 4 and 8 hr. The lysosome inhibitors
leupeptin and pepstatin failed to increase S662G hPER2 protein.
(H) Control cells were treated with vehicle (DMSO) at t = 0 for the 4 hr time point and at t = 0 and t = 4 for the 8 hr time point.Cell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc. 63
Figure 4. Expression Levels of Clock Genes in S662G, S662WT, and S662D Transgenic Mice in Liver (A and B, D and E, and G–J)
and in Fibroblasts (C and F)
(A and B) Both mPer2 (A) and hPER2 (B) mRNAs peak earlier for S662G and later for S662D than for wild-type in liver from animals that are entrained
in LD12:12 and released into DD.
(C) hPER2 mRNA in synchronized fibroblast cultures was significantly higher at all time points for S662D versus S662G.
(D and E) Transcript levels of (D) mClock and (E) mCry1 at different time points in liver are not different in amplitude but peak earlier for S662G and later
for S662D relative to wild-type. Each value represents the mean of four independent experiments and was normalized to the corresponding Gapdh
levels.
(F) Rev-erba mRNA in fibroblasts was significantly lower in the dark phase for S662D versus S662G.
(G–J) Transcript levels of (G) mRev-erba, (H) mBmal1, and (I) mRora4 in liver peaked earlier and at higher levels in S662G versus S662D.
(J) hPER2 pre-mRNA levels mirrored both hPER2 and mPer2 mRNA profiles in liver. Error bars represent the standard deviation for each time point
in four independent experiments.64 Cell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc.
4B). In addition, the mRNA levels were lower for S662G
and higher for S662D when compared to wild-type, em-
phasizing again the dominant effect of these mutations.
We then examined message levels of the hPER2 mRNA
in fibroblasts from animals of both genotypes after serum
shock and showed that S662D message levels were
higher at all time points when compared to S662G
(Figure 4C). Since both mPer2 and hPER2message levels
are decreased in the S662G mice, this argues for altered
transcriptional activity rather than decreased S662G
hPER2 mRNA stability. In addition, analysis of hPER2
pre-mRNA (Ripperger and Schibler, 2006) showed the
same pattern as seen for hPER2 and mPer2 mRNA
(Figure 4J). Thus, changing the charge at residue 662
alters the ability of PER2 to regulate its own transcription,
presumably through interaction with other proteins, since
PER2 itself does not bind DNA (Reppert and Weaver,
2001).
The Primary Consequence of S662G Is Not Altered
PER2 Degradation or Nuclear Localization
In order to test whether protein degradation contributes to
these protein level differences, a proteasome inhibitor
(MG132) or lysosome inhibitors (leupeptin and pepstatin)
were added to fibroblast cultures from S662G, S662WT,
and S662D mice. While PER2 was abundant both before
and after treatmentwith either proteasomeor lysosome in-
hibitors in both S662WT and S662D, S662G PER2 could
not be visualized, even after application of the inhibitors.
Thus, the reduced PER2 levels in S662G fibroblasts
results primarily from decreased PER2 transcription rather
thanalterations in protein degradation (Figures 3F–3H). It is
still possible that the mutation also affects PER2 stability.
We then set out to test whether the S662G or S662D
mutations affected nuclear translocation of PER2. Initially,
we began using transfection of cultured HEK293 cells with
hPER2 cDNAs driven by ubiquitous promoters and
showed that a large amount of overexpressed protein
was present but that there was no difference in subcellular
localization among the different genotypes (Figures S2A–
S2C). Because of concern that overexpression of hPER2
in cells may not reflect normal PER2 cellular localization,
we used the hPER2 promoter (15 kb upstream of the
ATG start site) to drive expression of wild-type, S662G,
and S662D PER2 cDNAs as fusion proteins with GFP. Us-
ing the hPER2 promoter, PER2 is largely (if not exclusively)
a nuclear protein, and no changes in localization were
recognized among the genotypes (Figures S2D–S2O).
Quantification of data is shown for cytomegalovirus
(CMV) (Figure S2P) and hPER2 promoters (Figure S2Q).
We cultured fibroblast cells fromCry1/Cry2 double knock-
out mice to examine whether PER2 nuclear entry requires
CRY. Nuclear localization was observed in 95% of cells
when transfected with hPER2 (Figure S2R). These data
demonstrate that changing the amino acid at position
662 does not affect PER2 cellular localization or nuclear
translocation and that PER2 nuclear entry is independent
of CRY1 and 2.Changing CKId Dosage Modulates Phenotype
of S662 Mutants but Not Wild-Type Per2
Neither CKId +/ animals nor CKId WT transgenic mice
have an altered circadian t (Figure 5). We next crossed
the PER2 transgenic mice with both CKId WT transgenic
and heterozygous CKId knockout mice. The S662G allele
leads to a short t (22 hr, Figure 2A). When S662G is
crossed onto a background with a WT CKId transgene, t
gets even shorter (20.8 hr. Figure 5 and Table S2). Cross-
ing S662G onto a CKId heterozygous null background
Figure 5. Altered CKId Dose Modifies Expression of S662G
and S662D Circadian Phenotypes
Representative locomotor activity records of representative mice with
the indicated genotypes are shown on the left. The right panel shows t
of these mice as determined by chi-square periodgram analysis. (See
Table S2 for population data.)Cell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc. 65
Figure 6. Model of CKId Regulation of Per2
(A) The kinase (CKI) acts on at least two Per2 sites. Phosphorylation at one (??) leads to degradation of Per2. After phosphorylation of S662 by a
priming kinase (green), CKI is able to phosphorylate a series of downstream serines. This leads to increased Per2mRNA and protein. The equilibrium
results in Per2 levels that dictate period length.
(B and C) Removal of one copy of CKId by homologous recombination (CKId +/), or (C) addition of one to two genomic copies of a CKId transgene
does not change the period because of maintenance of the balance of these opposing affects.
(D) The inability of the priming kinase to phosphorylate S662G leads to hypophosphorylation of the downstream residues by CKI. The net effect
is decreased Per2 and shortening of the period.
(E) Crossing the S662G transgene onto a heterozygousCKId knockout partially corrects the shortening conferred by S662G by decreasing phosphor-
ylation mediated Per2 degradation.
(F) In the S662G mouse, addition of one to two CKId genomic transgenes now shortens the period further as increased degradation is not opposed
by transcription regulation from phosphorylation downstream of residue 662.partially corrects t shortening of S662G (22.5 hr, Figure 5
and Table S2). The t of S662D transgenic mice becomes
even longer on a CKId +/ background (25 hr, Figure 5
and Table S2).
In vitro transfection assays of wild-type and mutant
Per2 phosphorylation by CKI have previously shown that
the region immediately C-terminal of S662 is not the sole
CKI phosphorylation site on Per2 (Eide et al., 2005). Since
the phosphorylation cascade downstream of S662 leads
to increased Per2 levels (via increased Per2 transcription),
and the S662G mutation leads to decreased Per2 levels,
we propose that phosphorylation of another site on Per2
by CKI targets Per2 for degradation. Another theoretical
possibility is that CKId is mediating this effect indirectly
through phosphorylation of another substrate. We favor
the former model based on work in Drosophila and in
cell culture showing that phosphorylation of Per leads to
Per degradation.
Taken together, these data support a model where CKI,
through different phosphorylation sites, is playing oppos-
ing roles in the regulation of PER2 levels (Figure 6A). PER2
protein levels are balanced by opposing actions of CKI in
increasing PER2 degradation (left side) versus increasing
PER2 transcription (and thus, protein levels, right side).
Data from S662D, showing increased PER2 message66 Cell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc.suggests that phosphorylation of this motif leads to acti-
vation of PER2 expression. Changes in CKId copy number
affect both regulatory actions in opposite directions and
to approximately equal extents, thus causing no change
in t (Figures 6B and 6C). The S662G mutation interferes
with the downstream phosphorylation cascade, resulting
in lower rates of PER2 transcription and less PER2 protein
(Figure 6D). Phosphorylation by CKI at another site con-
tinues to target PER2 for degradation, thus disrupting
the balance toward lower PER2 levels and shorter t.
Increased CKId dosage further accelerates PER2 degra-
dation of S662G, leading to an even shorter t (Figure 6F),
while CKId haploinsufficiency partially corrects t shorten-
ing caused by this mutation (Figure 6E).
This model also fits with a recent report demonstrating
that all CKI short-period mutations tested enhance the
phosphorylation of Per proteins in cells but that not all of
them accelerated the degradation of Per (Gallego et al.,
2006). It is interesting to speculate that the CKI mutations
leading to increased degradation may result in increased
phosphorylation of one Per2 site and that those not affect-
ing degradation have affects on phosphorylation of
another site(s). They postulated distinct regulatory sites
that fit with our model (Figure 6A). Gain-of-function muta-
tions in the kinase at a site leading to degradation would
produce similar downstream effects (decreased Per2
levels) to a mutation decreasing the ability of another
phosphorylation site on the substrate (downstream of
S662G, for example) to mediate increases in Per2 expres-
sion and protein.
Cycling of Other Clock Genes
The expression profile of clock-related genes (mCry1,
mBmal1, mClock, mRora, and mRev-erba) was analyzed
to investigate themolecular mechanism underlying t alter-
ations (Figure 4). Clock and Cry1 expression were rhyth-
mic and followed the same altered pattern of peak expres-
sion: S662G shifted forward and S662D shifted backward
when compared to S662WT (Figures 4D and 4E), with a 4
hr phase difference between S662G and S662D. The RNA
oscillations of these clock genes are consistent with pre-
vious reports (Albrecht et al., 1997; Lee et al., 2001; Zylka
et al., 1998), and the expression levels are similar in
S662WT, S662G, and S662D transgenic mice.
PER2 has been postulated to be a negative regulator of
mRev-erba expression (Preitner et al., 2002). The peak
expression of Rev-erba is significantly higher in S662G
than in S662D, and the phase is advanced at least 8hr in
S662G mice when compared to S662D mice (Figures 4F
and 4G). Given the dominant role of REV-ERBa in sup-
pressing Bmal1 transcription (Preitner et al., 2002),
Bmal1 expression should have been strongly inhibited in
S662G mice (with low PER2 levels and high Rev-erba
expression) compared with S662Dmice (high PER2 levels
and low expression of Rev-Erba). Unexpectedly, Bmal1
expression showed modest reduction in S662D mice
compared with S662G, although robust molecular oscilla-
tions persist in both transgenic lines (Figure 4H). The
trough level of Bmal1 was prolonged in the S662D and
shortened in S662G compared with S662WT mice. We
monitored expression of Rora in S662WT, S662G, and
S662D mice, since RORA is thought to activate Bmal1
transcription in competition with REV-ERBa transcrip-
tional repression (Emery and Reppert, 2004; Sato et al.,
2004). As described previously (Ueda et al., 2002), Rora
displayed no obvious cycling in liver. Rora expression
levels were also lower in S662D mice than in S662G
mice (Figure 4I). Expression levels of Rev-erba, Bmal1,
and Rora were different (S662G versus S662WT versus
S662D, Figures 4G–4I), while levels of Clock and Cry1
were unchanged (Figures 4D and 4E). This suggests that
abundance and/or phosphorylation of Per2 plays a role
in the regulation of the transcriptional loop involving
Rev-erba, Bmal1, and Rora, with Per2 potentially acting
as a negative regulator of Rora and Rev-erba expression.
DISCUSSION
The discovery of the S662G mutation causing human
FASPS was direct evidence that PER2 plays an essential
role in the human circadian clock. Mice transgenic for
S662G recapitulate the short t FASPS phenotype seen
in humans. Mice with a transgene encoding an acidic res-idue at position 662 showed t elongation. The fact that
a single amino acid change can produce such profoundly
different affects on t and phase angle of entrainment sug-
gests that this residue plays a central regulatory role in
period-length determination. Identification of the priming
kinase is an important future direction, since this enzyme
plays a key PER2 regulatory role.
These mouse models provide exciting opportunities to
probe changes in circadian regulation in vivo. It is intrigu-
ing that the mPer2ldc allele on the C57BL/6J background
did not become arrhythmic, at least for the 2–3 weeks
these animals were maintained in DD. Genotypes were
double checked to confirm that these mice are homozy-
gous for the knocked-out allele. In addition, western
analysis demonstrated no Per2 protein in tissue from
these mice. Finally, period changes in S662 mutant trans-
genic mice were further exaggerated when crossed onto
the Per2/ background.
Mice with one or two copies of an hPER2 S662G trans-
gene had an average circadian t that was significantly
shorter than the one circadian t (23.3 hr) so far reported
from a heterozygous S662G human (Jones et al., 1999).
The relative endogenous periods of mice and humans
carrying the same circadian mutation have not previously
been reported, and therefore the reasons for this discrep-
ancy are not known with certainty. Possible explanations
include differences in human versus mouse circadian
function or in experimental design. As one example of
the latter, we note that the one t measurement in a
S662G gene carrier was obtained from a paradigm (Jones
et al., 1999) that is different from the mouse experiments
and considered by some to overestimate t (Campbell,
2000; Czeisler et al., 1999; Klerman et al., 1996). More
comparisons of human and murine circadian phenotypes
under the influence of the same human clock genes are
needed to enhance the applicability of murine models to
human circadian disorders.
The changes in t seen in S662G and S662D mice with
two endogenous wild-type alleles (but not the wild-type
transgenics) demonstrate that the S662G and S662D
mutations are dominant. In vivo experiments in these
mice showed PER2 mRNA and protein to be decreased
in S662G and increased in S662D when compared to
wild-type. These phenotypes were even more exagger-
ated when the mutant transgenes were crossed onto
Per2/. Having ruled out increased degradation and
altered nuclear translocation of PER2 in S662G mice as
the primary cause of decreased mRNA and protein, the
remaining possibility is that the mutation affects transcrip-
tional regulation of hPER2 and mPer2 with S662G leading
to decreased Per2 expression, and S662D leads to in-
creased Per2 expression. We cannot rule out the possibil-
ity that the mutation also alters RNA or protein stability.
However, the S662G hPER2 protein alters expression of
the endogenous mPer2 locus (trans-effect), demonstrat-
ing that this is the relevant consequence for the circadian
phenotype. Our data also support differential regulation of
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S662G and phase delayed in S662D. However, Cry1
mRNA levels were the same for all three PER2 genotypes,
while PER2 mRNA was decreased in S662G and in-
creased in S662D when compared to wild-type.
An important future direction is to elucidate the mecha-
nism whereby charge changes at PER2 residue 662 regu-
lating downstream phosphorylation can change transcrip-
tional activity. PER2 does not bind DNA itself and, thus,
must exert these effects through other partners. This
effect must be through CLOCK/BMAL, either directly or
indirectly.
One plausible model involves the cell sensing PER2
levels changing over time. A new cycle begins as PER2
levels drop below a critical threshold. PER2 gene expres-
sion is activated followed 4–6 hr later by activation ofCRY.
PER2 and CRY accumulate until CRY levels reach a
threshold at which PER2 expression is turned off. PER2
protein degrades, and a cycle ends, when PER2 levels
drop below the threshold, thus initiating the next cycle.
In S662G individuals or mice, the resulting alteration in
transcription leads to production of less PER2 mRNA
and protein. Phosphorylation at another site targeting
PER2 for degradation is unaffected (Figure 6). Thus, PER2
levels are lower at all time points and, in the latter half of
a cycle, fall below the threshold earlier than wild-type,
leading to activation of transcription earlier and resulting
in a shorter t. There is a higher abundance of PER2 in
the nuclei of S662D mice, resulting from increased tran-
scriptional activation due to hyperphosphorylation down-
stream of S662. Thus, cellular machinery takes longer to
degrade the protein to levels below the threshold, leading
to a delay in activation of expression in the next cycle
relative to wild-type (and thus, to a longer t). This model
explains the codominance of both mutations with wild-
type. Consistent with the data, this model predicts that
CRY repression of PER2 transcription would be dominant
over the transcriptional activator(s) of PER2. Wild-type
PER2 results in higher PER2 mRNA and protein levels
in vitro and in vivo (and S662D in even higher levels). Thus,
it is clear that PER2 must also be involved in transcrip-
tional activation of PER2, likely through regulation of
PER2 abundance and/or regulation of particular PER2
phosphorylation states.
EXPERIMENTAL PROCEDURES
Synthetic Peptides
Pep-2U and Pep-2P incorporate residues 659–674 of hPER2 and
includes basic amino acids at their N terminals. S662 is phosphory-
lated in Pep-2P. APC2 is peptide incorporating residues 1386–1402
of the human APC protein. All peptides were purified with high-
performance liquid chromatography (HPLC) and confirmed with
mass spectrometry.
In Vitro Phosphorylation
Peptides at 10 mM concentration were phosphorylated in buffer
containing 30 mM HEPES at pH7.5, 7 mM MgCl2, 250 mM ATP,
0.5 mM DTT, 0.1 mg/ml bovine albumin, and a small amount of
g32P-ATP. In initial experiments comparing Pep-2U and Pep-2P phos-
phorylation, his-tagged full-length CKI3was used at a concentration of68 Cell 128, 59–70, January 12, 2007 ª2007 Elsevier Inc.0.4 ng/ml. In the experiments to determine phosphorylation stoichiom-
etry, a his-tagged truncated version of CKI3 lacking the autoregulatory
C-terminal tail was used at a concentration of 1.5 ng/ml to ensure com-
plete peptide phosphorylation over the longer periods needed for
these experiments. At selected time points, 20 ml aliquots were
removed andmixed with 50 ml 30% acetic acid to inactivate the kinase.
The mixtures are spotted onto Whatman P81 paper, allowed to dry,
and then washed with 74 mM orthophosphoric acid three times for
5 min. The Cerenkov radiation of the labeled peptides was counted.
To calculate the stoichiometry of the phosphorylations, serial dilu-
tions of the kinase reaction mixes were prepared at the end of each
experiment and spotted onto P81 circles. The unwashed circles
were placed in scintillation vials, and the Cerenkov radiation was
counted. Based on the concentrations of unlabeled ATP (present in
excess) and peptide, the specific activity of the ATP and the moles
of phosphate transferred per mole of peptide were then calculated.
These experiments were performed in triplicate.
Phosphoamino Acid Analysis
Reaction mixes containing peptides that had been phosphorylated
for 24 hr were passed through Microcon 10 (Amicon) filter devices.
The radioactive species in the filtrate consisted only of labeled pep-
tides (molecular mass less than 3 KD) and unincorporated g32P-ATP.
Thirty microliters aliquots of the filtrate were spotted onto P81 circles,
allowed to dry and washed with o-phosphoric acid to remove the ATP.
The washed circles were air-dried and the labeled peptides eluted
with freshly prepared 50 mM NH4HCO3. The peptides were dried
and washed once with distilled water and once with pH 1.9 buffer
(0.58 M formic acid, 1.36 M acetic acid). The peptides were dried after
each wash with Speed vac concentrator.
The washed peptides were resuspended in 6 M HCl and incubated
at 110C to hydrolyze them to their constituent amino acids. After cool-
ing to room temperature, the samples were transferred to fresh tubes,
dried, and the Cerenkov radiation counted before the peptides were
dissolved in pH 1.9 buffer. Equal counts of hydorlysate were spotted
onto thin layer cellulose (TLC) plastic sheets (EM Science) with a solu-
tion containing 2 mg/ml of phosphoserine, phosphothreonine, and
phosphotyrosine standards and electrophoresed in two dimensions
with pH 1.9 and pH 3.5 buffer, respectively, using a previously de-
scribed protocol (Boyle et al., 1991). (pH 3.5 buffer contained 0.87 M
acetic acid, 0.5% v/v pyridine, and 0.5 mM EDTA.) The sheets were
dried, sprayed with 0.2% ninhydrin in ethanol solution (Sigma), and
baked at 80C for 10 min to visualize the phosphoamino acid stan-
dards. Radiolabeled alignment markers were spotted onto the dried
sheets and the radioactive spots containing g32P-ATP, phosphoamino
acids, and partially hydrolyzed peptides were visualized with Phos-
phorImager screens scanned with Scanner Control SI software
(Molecular Dynamics) after overnight exposure. These experiments
were performed in duplicate.
Transgenesis, Breeding, and Animal Behavior Analysis
Animal studies were approved by the Animal Care and Use Committee
at UCSF. Generation of transgenic animals and locomotor activity and
activity pattern analysis were performed as described previously (Xu
et al., 2005). Since Per2/, S662WT, S662G, S662D, CKId wild-type
transgenic, and CKId +/ animals were all on a C57BL/6J background,
animals could be crossed without requiring generations of backcross-
ing to generate a homogeneous background. Animals were genotyped
using standard protocols.
Western Blotting and Immunoprecipitation (IP)
Fresh liver extracts from designated circadian times were prepared
according to nuclear extraction kit (Actif Motif, http://www.
activemotif.com/home) manufacturer’s protocol with the following
modification: briefly, 100 mg fresh liver was washed with 5 ml ice-
cold PBS/Phosphatase Inhibitors and transferred to 500 ml ice-cold
1 XHypotonic buffer supplementedwith 5 ml 1MDTT and 5 ml detergent
and homogenized. After centrifugation for 10min at 850 X g, cells were
gently resuspended in 500 ml 1 X Hypotonic buffer for another 15 min
and centrifuged as before. The nuclear pellet was resuspended in
50 ml complete lysis buffer with 10 times protein inhibitor cocktail. The
Active Motif protocol was then followed through extraction of nuclear
protein. All procedures were performed in 4C. Cytoplasmic and nu-
clear fractions were quantified with the Bicinchoninic Acid protein as-
say kit (Pierce) and aliquoted in liquid nitrogen. For fibroblast cells,
cells were harvested from 90mmdishes at the indicated times after se-
rum shock. In order to increase the visibility of S662G PER2 in
Figure 3E, this procedure was modified as follows: 10 times less vol-
ume of hypotonic buffer and nuclear lysis buffer with 10 times protein
inhibitors were employed to purify cytoplasmic and nuclear fractions.
The cytoplasmic and nuclear fractions were mixed with 4 3 sample
buffer and boiled for 3min. Proteins were separated by electrophoresis
through sodium dodecyl sulfate (SDS)-6% polyacrylamide gels (acryl-
amide 29.6 g: bisacrylamide 0.4 g) and then transferred to nitrocellu-
lose membranes. Membranes were blocked with 3% nonfat dry milk
in Tris-buffered saline containing 0.05% Tween 20 and then incubated
with hPER2 antibody (Cosmo Bio, Japan) (Miyazaki et al., 2004).
Immunoreactive bands were detected using anti-rabbit immunoglobu-
lin G secondary antisera and ECL (Amersham). These experiments
were performed in triplicate.
Primary Fibroblast Culture from Humans and Mice
Skin biopsies were obtained on a protocol approved by the IRBs at the
University of Utah and UCSF. A standard 4 mm skin punch biopsy was
performed on the lower leg. Biopsy tissue was cut into several pieces
and allowed to adhere onto 35 mm culture dishes for 10 min. Two
milliliter 10% FCS of DMEM with 5 mM glutamine was added to the
dish and incubated at 37C in a humidified 5% CO2 atmosphere.
Explants were monitored for appearance of cells along the edges of
tissue pieces every 2 days, and media was changed weekly. Out-
growth of spindle-shaped fibroblasts usually occurred within the first
10 days. Keratinocytes appeared prior to fibroblasts but then differen-
tiated and died in passage. When fibroblast outgrowth reached a size
of about 1 cm2 (2–4 weeks), tissue pieces were removed gently into
a new dish and were cultured again as before. Added to the dishes
was 0.3 ml 0.25% trypsin until cells began to detach. Added was
1.5 ml of DMEM (10% FCS), and cells were placed into new 35 mm
dishes. Primary cultured fibroblasts were grown to confluence in
10 mm dishes and starved of serum for 24 hr before synchronization.
Cells were harvested at indicated time points. Cytoplasmic and
nuclear fractions were analyzed on western blots. The mouse embry-
onic fibroblasts were isolated from embryos at day E13.5 following
standard procedures (Abbondanzo et al., 1993).
Protein Degradation and Stability
Confluent cells were culturedwith serum-free DMEM for 24 hr and then
were stimulated with 50% horse serum for 2 hr. Proteasome inhibitor
(MG132, 50 mM, Calbiochem) was added at t = 0 and added again at
4 hr. Lysosome inhibitors (leupeptin, 100 mM and pepstatin, 100 mM,
Roche) were added to cells 2 hr after serum shock and 2hr before cells
were harvested. After treatment with inhibitors, cell extracts were pre-
pared as described above at the times indicated. The Bicinchoninic
Acid protein assay kit (Pierce) was applied to adjust for protein amount.
Antibody to Tubulin was used as loading control. Control cells were
treated with vehicle alone (DMSO) 2 hr after serum shock. These
experiments were performed in triplicate.
Quantitative RT-PCR
Total RNA was extracted using Trizol (Invitrogen), and random hexam-
ers were used to prime reverse-transcription reactions with Super-
script III (Invitrogen). Real-time quantitative PCR was performed using
an ABI 7700 with SYBR green I reagents. The RT-PCR primers were as
previously reported (Yamamoto et al., 2004). Efficiency of amplification
and detection by all primers was validated by determining the slope ofthreshold cycle versus dilution series. Transcript levels for each gene
were normalized to Gapdh mRNA levels according to standard proce-
dures. For hPER2 Pre-mRNA accumulation, primers 50 GGGCGATTC
TCTTTTGGGA30, 50 CCTTGGTTTCCTTGGCCTTC30 and probe FAM-
CCCTCCCTCCCCTCGCATGG-TAMRA were used to amplify nuclear
RNA by real-time RT-PCR according to gene-specific primer (GSP)
protocol (Invitrogen) (Ripperger and Schibler, 2006). These experi-
ments were performed in triplicate.
Plasmid Constructs
The coding region of hPER2 was amplified from human cDNA by PCR
using Platinum Taq polymerase and cloned into pCMV-Tag 2B (Prom-
ega). QuikChange site-Directed mutagenesis was used to construct
hPER2S662G and S662D vectors (Stratagene). The vectors were
further modified by adding enhanced green fluorescent protein
(EGFP). The hPER2 promoter was generated by applying Red/ET
recombinant technology and cut off from BAC clone.
Transient Transfection and Nuclear Localization Assays
HEK293 cells were plated in 35 mm dishes at a density of 3 3 105 for
24 hr before transfected by PolyFect (Qiagen). The fibroblast cells were
transfected by LipofectAmine 2000 with Plus reagent (Invitrogen). At
indicated time points, cells were fixed with 4% paraformaldehyde,
washed with PBS, and mounted with DAPI mounting medium
(VECTOR). A random population of 100 cells from each coverslip
was examined by confocal laser scanning microscope (Zeiss).
Supplemental Data
Supplemental Data include two figures and two tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
128/1/59/DC1/.
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